Medical technology firm Glaukos has closed enrollment in its US Food and Drug Administration (FDA) investigational device exemption (IDE) trial of iStent SUPRA Suprachoroidal Micro-Bypass Stent for the treatment of glaucoma and cataract.

The 4mm in length and curved  iStent SUPRA is developed to decrease the intraocular pressure (IOP) by accessing the suprachoroidal space in the eye.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The prospective, randomised clinical trial will evaluate the stent in 505 participants with mild-to-moderate open-angle glaucoma and cataracts.

The primary objective of the trial is to achieve 20% or greater decrease in intraocular pressure (IOP) from baseline over a period of 24 months. Based on the results from this trial, the firm intends to submit for a pre-market approval (PMA) to the FDA.

Glaukos president and chief executive officer Thomas Burns said: “We expect the iStent SUPRA to ultimately be an important part of ophthalmic surgeons’ armamentarium for effectively managing IOP.

See Also:

“Achieving this enrollment milestone represents an important step forward in our goal to provide surgeons and their patients a comprehensive set of options to address a range of glaucoma disease state and progression.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"Achieving this enrollment milestone represents an important step forward in our goal to provide surgeons and their patients a comprehensive set of options to address a range of glaucoma disease state and progression."

iStent SUPRA is currently approved for marketing in the European Union and certain other countries outside the US.

In 2012, the firm has introduced iStent Trabecular Micro-Bypass Stent to perform micro-invasive glaucoma surgery by accessing the suprachoroidal space for aqueous humor outflow through the trabecular meshwork and into Schlemm’s canal.

Glaukos is conducting FDA clinical trials of the iStent inject Trabecular Micro-Bypass Stent, for its use in combination with cataract surgery and as a standalone procedure.

Image: iStent. Photo: courtesy of Glaukos Corporation.